Trial
NCT03225716
A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Dana-Farber Cancer Institute
Collaborators
Bristol-Myers Squibb
Condition
Waldenstrom's Macroglobulinemia
Intervention
Ulocuplumab
Why stopped
Sponsor decision to end follow-up early
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-05-03